# WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma

Source: https://onco.cc/trials/nct05678998/  
OnCo record `nct05678998` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of WTX-330 run by Werewolf Therapeutics, Inc., completed.

## Summary

WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma is a phase 1 interventional study registered as NCT05678998 by Werewolf Therapeutics, Inc., with 25 participants enrolled, started 2022-12-06. Conditions recorded: Advanced or Metastatic Solid Tumors and Non-Hodgkin Lymphoma. Interventions recorded: WTX-330.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05678998
- Phase: 1
- Setting: A Phase 1 (First-In-Human [FIH]), Multi-Site, Dose Escalation and Expansion Study of WTX-330 in Adult Patients With Advanced or Metastatic Solid Tumors or Lymphoma
- Sponsor: Werewolf Therapeutics, Inc.
- Enrolled: 25

## Sources

- ClinicalTrials.gov NCT05678998: https://clinicaltrials.gov/study/NCT05678998

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [WTX-330](https://onco.cc/drugs/wtx-330/)
- companies: [Werewolf Therapeutics](https://onco.cc/companies/werewolf-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct05678998.json